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Insulin-like growth factor-I (IGF-I) belongs to the family of polypeptides of insulin, which
play a central role in embryonic development and adult nervous system homeostasis by
endocrine, autocrine, and paracrine mechanisms. IGF-I is fundamental for the regulation of
cochlear development, growth, and differentiation, and its mutations are associated with
hearing loss in mice and men. Low levels of IGF-I have been shown to correlate with dif-
ferent human syndromes showing hearing loss and with presbyacusis. Animal models are
fundamental to understand the genetic, epigenetic, and environmental factors that con-
tribute to human hearing loss. In the mouse, IGF-I serum levels decrease with aging and
there is a concomitant hearing loss and retinal degeneration. In the Igf1−/− null mouse,
hearing loss is due to neuronal loss, poor innervation of the sensory hair cells, and age-
related stria vascularis alterations. In the inner ear, IGF-I actions aremediated by intracellular
signaling networks, RAF, AKT, and p38MAPK protein kinases modulate the expression and
activity of transcription factors, as AP1, MEF2, FoxM1, and FoxP3, leading to the regula-
tion of cell cycle and metabolism. Therapy with rhIGF-I has been approved in humans for
the treatment of poor linear growth and certain neurodegenerative diseases. This review
will discuss these ﬁndings and their implications in new IGF-I-based treatments for the
protection or repair of hearing loss.
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IGF SYSTEM AND SIGNALING PATHWAYS
Early studies have provided evidences that the insulin-like growth
factor (IGF) system exerts inﬂuence on almost every organ system
in the body, playing an important function in growth, develop-
ment, and metabolism. The mammalian IGF system is a complex
family of proteins that includes three factors (insulin, IGF-I, and
IGF-II) and their cell surface receptors,which are the insulin recep-
tor (IR), the IGF receptors 1 and 2 (IGF1R, IGF2R), and hybrid
IGF1R/IR receptors. Six high-afﬁnity binding proteins (IGFBP1–
6) and their IGFBP proteases modulate the interactions between
factors and receptors (Figure 1).
Insulin-like growth factor-I is a single-chain 70 amino acid pep-
tide, mainly secreted by the liver (Foulstone et al., 2005). At the
surface of target cells, the biological actions of the IGFs are medi-
ated by receptors responsible for the transmission to a highly reg-
ulated intracellular signaling network. IGF1R, a transmembrane
tyrosine kinase receptor, shares functional and structural homol-
ogywith the IR, and can bind IGF-I and insulin, the latter onlywith
a 100-fold lower afﬁnity than IGF-I (Annunziata et al., 2010). The
IGF1R is a tetramer with an intracellular protein tyrosine kinase
domain (Adams et al., 2000; De Meyts and Whittaker, 2002). The
close homology between IGF1R and IR allows the formation of
functional hybrid receptors (Pandini et al., 2002; Torres-Aleman,
2010). The biological role of hybrid receptors has not been exten-
sively tested and needs further investigation (Belﬁore et al., 2009;
Beauchamp et al., 2010). Finally, IGF2R, the cation-independent
mannose-6-phosphate receptor, is a transmembrane glycoprotein
without tyrosine kinase activity (Morgan et al., 1987). The IGF2R
binds IGF-II but is unable to bind IGF-I (Brown et al., 2009).
IGF system actions are regulated by a family of six high-afﬁnity
secreted binding proteins (IGFBPs1–6) that act modulating the
half-life anddistribution of the IGFs and competingwith receptors
for free ligands (Federici et al., 1997; Firth and Baxter, 2002). The
IGFBP family also includes a group of low-afﬁnity IGFBP-related
proteins (Jiang et al., 2008).
Insulin-like growth factor signaling occurs via a complex intra-
cellular network of molecules, where the cascade(s) triggered
depend on the cellular spatiotemporal context and is determined
by the ligands and receptors involved (Figure 2). It was already
known that signaling mediated by these tyrosine kinase receptors
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FIGURE 1 | Insulin-like growth factor system.
regulates pancreatic β cell function, but it has been recently con-
cluded that IGF1R and IR signaling modulate insulin secretion
and cell proliferation differently through their actions on IRS1
or IRS2, respectively (Xuan et al., 2010). IGF-I binding to IGF1R
results in its autophosphorylation and activation of docking sites
for receptor substrates (Shc/IRS; Laviola et al., 2008). Activation of
IGF1R triggers twomain downstreampathways: the PI3K–Akt and
the RAF/ERK cascade. Both have been shown to play an important
role in the transmission of signals from cellmembrane receptors to
the nucleus through interactions with other proteins (Mccubrey
et al., 2011). On the ﬁrst pathway, one of the critical targets is
the serine/threonine kinase Akt that regulates protein synthesis
and antiapoptotic effects of IGF1R (Laviola et al., 2008). In turn,
activation of the RAF/ERK cascade participates in cell growth,
proliferation, and differentiation (Downward, 2003; Mebratu and
Tesfaigzi, 2009). Other well-documented kinases modulated in
response to IGF-I are SAPK (stress-activated protein kinase) and
the p38 MAP kinase activated by different stress stimuli (Cuenda
and Nebreda, 2009; Vardatsikos et al., 2009).
MUTATIONS OF THE GENES OF THE IGF SYSTEM AND
HUMAN DEAFNESS
Main molecular defects in the IGF system include mutations of
the IGF1 gene and mutations of the IGF-I high-afﬁnity receptor
gene (IGF1R).
MUTATIONS OF THE IGF1 GENE
Homozygote mutations of the IGF1 gene are extremely rare and
only four cases have been reported (Woods et al., 1996; Bona-
pace et al., 2003; Walenkamp et al., 2005; Netchine et al., 2009).
These patients have in common the features of severe intrauterine
growth retardation, and some degree of microcephaly. However,
sensorineural deafness is not constant and the intensity of delayed
psychomotor development is variable. Severe or profound hearing
loss has been described in three of the four cases. Table 1 shows the
main features of homozygous mutations of the IGF1 gene. In the
fourth case reported, an extensive hearing test performed at 9 years
of age was normal. This child also showed the mildest phenotype
since the mutation allows IGF-I synthesis although with reduced
afﬁnity for its receptor (Netchine et al., 2009).
Accordingly, heterozygosis for IGF1 mutations is associated
with a modest decrease of height, but hearing loss has not been
reported in these patients. A case of partial IGF-I deﬁciency has
recently been described and was associated with pre and postna-
tal growth retardation and microcephaly, but the developmental
delay was mild and hearing tests were normal (Van Duyvenvoorde
et al., 2010). Sensorineural hearing loss is associated with poor
growth rates in infancy and adolescence (Welch and Dawes, 2007),
adult short stature (Barrenas et al., 2005), and Turner’s syndrome
(Barrenas et al., 2000).
MUTATIONS OF THE IGF-I RECEPTOR GENE (IGF1R)
IGF1R mutations are characterized by IGF-I resistance causing
impaired fetal and postnatal growth. Ester et al. (2009) reported
hearing problems in two cases of IGF1R mutations. No data about
audiograms or electrophysiological tests were provided. The fact
that craniofacial anomalieswere present, and tympanostomy tubes
were inserted in both cases suggests that hearing loss could be
conductive, and the link to IGF-I resistance remains unproved.
Other authors reporting human IGF1R mutations did not ﬁnd
marked hearing loss (Klammt et al., 2011). The fact that no pro-
found sensorineural deafness has been reported in patients with
heterozygous IGF1 or IGF1R defects suggest that partial IGF-I
signaling is sufﬁcient for normal development of the inner ear.
NERVOUS SYSTEM ALTERATIONS ASSOCIATED WITH Igf1
MUTATIONS IN MICE
Studies of mutant mice with altered IGF-I expression show that
this factor exerts a variety of actions that take place in the nervous
systemduring neural cell development as well as in adulthood, and
highlights the fact that IGF-I contributes to neurogenesis by pro-
moting proliferation, differentiation, and survival of neural cells
(D’ercole et al., 2002; Liu et al., 2009).
The Igf1−/− null mice present reduced brain size and altered
brain regions, where the hippocampus, cerebellum, and cerebral
cortex are the most affected, along with alteration of myelination
processes (Ye et al., 2002a,b). Postnatal in vivo imaging by RMN
has shown that the olfactory bulb is reduced and disorganized,
in addition to reduced brain size and other brain and cranium
malformations (Riquelme et al., 2010). The number of myelinated
ﬁbbers is normal,butwhole ﬁbber size is reduced (Gao et al., 1999).
In mice with absent or reduced IGF-I levels, motor, and sensory
conduction velocities are signiﬁcantly decreased (Sullivan et al.,
2008). These mice also present a decrease in dendrite length and
complexity in the cortex, togetherwith a smaller pyramidal neuron
soma size (Cheng et al., 2003). Previous reports showed that the
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FIGURE 2 | Insulin-like growth factor-I signaling.
Table 1 | Reported cases with homozygous mutations of the IGF1 gene.
Woods et al. (1996) Bonapace et al. (2003) Walenkamp et al. (2005),
Walenkamp andWit (2007)
Netchine et al. (2009)
Sex Male Male Male Male
Consanguinity Yes Yes Yes Yes
Birth weight SDS/g −3.9/1400 −4.0/1480 −2.5/1420 −2.5/2350
Birth length SDS/cm −5.4/37.8 −6.5/41 −3/39 −3.7/44
Growth SDS −6.9 at 16 years −6.2 at 1.6 years −9 at 5 years −4.5 at 3 years
Sensorineural hearing loss Profound Severe Profound No
IGF-I levels Undetectable 1.0 ng/mL +7.3 SDS Variable
IGF-I afﬁnity-for IGF1R Zero Not studied Extremely low Partially reduced
Molecular defect Deletion of exons 4–5 Polymorphism Missense mutation V44M Missense mutation R36Q
IGF-I knockout has a lower number of neurons and oligodendro-
cytes in the olfactory bulb, dentate gyrus, and striatum (Liu et al.,
1993; Beck et al., 1995; Cheng et al., 1998) along with a decrease
in the cochlear ganglion neurons (Camarero et al., 2001). This
appears to be the result of various processes such as decreased cell
proliferation, delayed development, and increased cell death (Beck
et al., 1995; Camarero et al., 2001; Ye et al., 2002b; Ye and D’ercole,
2006; Sanchez-Calderon et al., 2010). Studies with Igf1−/− mice
during embryonic and adult neurogenesis suggest possible new
functions of IGF-I as the regulation of neuronal migration and
disposition in the olfactory bulb, the neuroblast output from the
subventricular zone and incorporation into the rostral migratory
stream, as well as the entry of new neurons from subventricular
zone to the olfactory bulb (Hurtado-Chong et al., 2009). A con-
ditional mouse mutant (Igf1r), with targeted manipulation of
Igf1r gene by CaMKIIα-Cre recombination in the central nervous
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system, in which the oligodendrocyte progenitors do not accumu-
late, proliferate, or survive, has been the preferred model to study
the role of IGF-I signaling in remyelinating lesions (Mason et al.,
2003).
Otherwise the transgenic mouse with IGF-I overexpression in
the brain presents increased brain size and cell numbers in all
neural lineages during embryonic and early postnatal develop-
ment, whereas hippocampus and cerebellum sizes are increased
postnatally. Previous studies have shown a proportional increase
in the number of neurons, astrocytes, and oligodendrocytes in the
dentate gyra of mice expressing an IGF-I transgene speciﬁcally in
astrocytes, indicating that the development of these cell lineages
was similarly affected by the IGF-I transgene (Ye and D’ercole,
2006). The potential role of IGF-I during embryonic and early
postnatal brain development was investigated in a transgenic mice
(IGF-I nestin Tg mice) with IGF-I overexpression driven from
early in embryogenesis by regulatory sequences from the nestin
gene. In this case, the neuron progenitor proliferation in the cere-
bral cortical ventricular and subventricular zones is performed by
shortening the length of the cell cycle G1 phase and an accumula-
tion of progenitors in themitotic cell cycle. IGF-I promotes growth
of the central nervous system in these stages of development by
mechanisms that involve both neural progenitor proliferation and
reduced apoptosis during the postnatal phase (Hodge et al., 2004;
Popken et al., 2004).
On the other hand, single and double mutant mice for IGF-I
and leukemia inhibitory factor (LIF) have been used to analyze
the neural embryonic phenotype, and the results suggest that both
factors decrease motoneuron number in speciﬁc brain stem nuclei
(Vicario-Abejon et al., 2004). Finally, the comparison of the brain
phenotype of Igf1 mutants carrying a deletion either in the liver
gene or in the forebrain neurons have lead to the conclusion
that circulating IGF-I plays an important role in brain function
(reviewed in Torres-Aleman, 2010).
In conclusion, transgenic mouse models are valuable tools
for better understanding of IGF-I mechanisms in the nervous
system, albeit further investigation is needed to understand the
organ-speciﬁc actions and to explore possible therapies.
Sensory systems are also affected by IGF-I deﬁcit, particular
attention has been devoted to the study of hearing because of the
human phenotype (Figure 3).
ANIMAL MODELS FOR THE STUDY OF IGF-I ACTIONS ON THE
INNER EAR
The mammalian inner ear develops from an ectodermal patch,
the otic placode, which invaginates to form the otic cup that
subsequently closes and forms the otic vesicle. This autonomous
structure contains the information required to generate the adult
inner ear (Bissonnette and Fekete, 1996; Sanchez-Calderon et al.,
2007). Organogenesis involves a dynamic balance of cell prolifera-
tion, differentiation, survival, and death, biological processes that
are tightly regulated by a network of extrinsic and intrinsic factors
(Sanchez-Calderon et al., 2007; Magarinos et al., 2010). Among
them, the IGF-I plays a key role in promoting proliferation and sur-
vival of otic progenitor cells and in supporting neurogenesis and
late differentiation (Frago et al., 2003; Varela-Nieto et al., 2007).
FIGURE 3 | Main features of the neural (A) and cochlear (B) phenotype
of the Igf1−/− null mouse. Data have been compiled from Liu et al. (1993),
Beck et al. (1995), Cheng et al. (1998), Gao et al. (1999), Camarero et al.
(2001, 2002), Ye et al. (2002a,b), Cediel et al. (2006), Sullivan et al. (2008),
Riquelme et al. (2010).
During cochlear development, this factor and its speciﬁc recep-
tor IGF1R are expressed in abundance in several species (Groigno
et al., 1999;Varela-Nieto et al., 2003; Sanchez-Calderon et al., 2007,
2010; Gross et al., 2008); however the transcription of both lig-
and and receptor declines signiﬁcantly after birth (Baker et al.,
1993; Stratikopoulos et al., 2008; Riquelme et al., 2010; Sanchez-
Calderon et al., 2010). In a variety of neural cell types, IGF-I is
able to induce growth and DNA synthesis, i.e., in the chicken otic
precursors (Leon et al., 1995; Rodriguez-De La Rosa et al., submit-
ted), to short the length of the cell cycle, to increase the number of
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progenitors and to prevent apoptosis (Varela-Nieto et al., 2003; Ye
and D’ercole, 2006). Thus IGF-I is essential for the proliferation,
survival, and early differentiation of inner ear neuronal precursors
(Varela-Nieto et al., 2004, 2007).
The lack of IGF-I causes signiﬁcant defects in the inner ear
in different species, including zebra ﬁsh (Schlueter et al., 2007),
chicken (Camarero et al., 2003), rat (Zheng et al., 1997), mice
(Camarero et al., 2001, 2002; Cediel et al., 2006), and men
(Walenkamp and Wit, 2007). Currently, there are several animal
models available with mutations in different IGF-I signaling path-
way components, which could be used to study the effects of
the deﬁcit in inner ear development. Regarding to mice, there
are genetically modiﬁed strains with mutations in the factors
(IGF-I and II), the receptor (IGF1R, IGF2R, and insulin recep-
tor), and the IGF binding proteins (IGFBP1–5 and IGFBP7).
Detailed information about the category, allelic composition and
phenotype of the mutant lines can be obtained at the Mouse
Genome Database at the Mouse Genome Informatics website
(http://www.informatics.jax.org). Most of the IGF system mutant
mice present a phenotype that includes some of these features:
increased mortality, premature aging, growth deﬁcits small size,
infertility, endocrine changes, muscle–skeletal abnormalities, and
neural alterations. Hearing impairment has been described only
in the mutant mouse with a targeted (knockout) mutation in the
Igf1 gene (Igf1tm1Arge/Igf1tm1Arge; Liu et al., 1993). It was gener-
ated by Argiris Efstratiadis’ group by replacement of sequences
encoding part of exon 4 with a neomycin resistance gene. The
homozygous mutant mouse maintained in a hybrid background
(129S/SvEv*MF1) presents delayed inner ear development, abnor-
mal cochlear, and otic capsule morphology, degeneration of the
cochlear ganglion, aberrant innervation patterns, increased neural
apoptosis, and deﬁcits in myelination (Camarero et al., 2001, 2002;
Sanchez-Calderon et al., 2010). As a consequence, Igf1−/− null
mice develop a profound syndromic sensorineural hearing loss
with increased hearing threshold assessed by auditory brainstem
response recording. Furthermore, as discussed above for the ner-
vous system, the cochlea and the auditory central pathway present
poor myelinization and this is reﬂected in the delayed latencies
of the auditory brainstem responses (Cediel et al., 2006; Riquelme
et al., 2010). IGF-I deﬁciency induces caspase-dependent neuronal
apoptosis in the brain and also in the cochlea (Sanchez-Calderon
et al., 2007). However, the impact of IGF-I deﬁcit on the neuronal
populations of the central nuclei of the auditory pathway have not
been yet studied.
In addition to deafness, Igf1−/− null mice also show other
sensorial deﬁcits including olfactory and visual function (Vicario-
Abejon et al., 2003; Otaegi et al., 2006; Scolnick et al., 2008;
Hurtado-Chong et al., 2009; Riquelme et al., 2010; Rodriguez-
De La Rosa et al., submitted). Accordingly, the transcriptome of
the Igf1−/− cochlea when compared to that of the wild type mouse
showed expression changes inmultiple genes associatedwith hear-
ing and seeing (Table A1 in Appendix). It is remarkable that genes
as harmonin, Rp1h, and tubby, whose mutations have been asso-
ciated to retinitis pigmentosa and to the human Usher syndrome
are IGF-I targets in the mouse cochlea (Sanchez-Calderon et al.,
2010). Unfortunately, there are no data available on the hearing
phenotype of other IGF system mouse mutants.
PERSPECTIVES OF IGF-I THERAPY IN THE TREATMENT OF
DEAFNESS
In recent years, advances in the ﬁelds of human genetics and
the sequencing of the human and other species genomes had
prompted a step forward in the knowledge of hearing phys-
iopathology (Dror and Avraham, 2009). In parallel, the use of
animalmodels of deafness (Lewis andSteel,2010) and thedevelop-
ments in the ﬁelds of nanotechnology (Danti et al., 2009) and stem
cells (Rivolta, 2010) have opened new possibilities of therapeu-
tic intervention. Finally, advances in microsurgery and cochlear
implants technology have facilitated research on local drug deliv-
ery to the cochlea for hearing loss treatment (Rivera et al., sub-
mitted). Local recombinant human IGF-I application has been
reported to be useful for the treatment of noise induced hearing
loss in animals (Iwai et al., 2006; Lee et al., 2007). Recently, Naka-
gawa et al. (2010) have demonstrated that topical IGF-I application
using gelatine hydrogels is well tolerated and may be efﬁcacious
for hearing recovery in patients with sudden sensorineural hearing
loss that is resistant to systemic glucocorticoids. These recent data
open new perspectives for IGF-I in the treatment of deafness. Still,
further studies are required to conﬁrm the therapeutic potential of
IGF-I in hearing loss and the prognostic value of plasmatic IGF-I
levels.
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